Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2010-03-23

Clinical Trial Update: Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study) [Phase 2]

View source ↗

Summary

Phase 2 ARISE trial results evaluate rituximab's immunomodulatory effects in the synovial tissue of patients with rheumatoid arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rituxan (rituximab)

Snippet

Sponsor: University of California, San Diego | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2010-03-23